



Received on 16 August, 2017; received in revised form, 03 November, 2017; accepted, 12 November, 2017; published 01 June, 2018

IN-VITRO BIOLOGICAL ACTIVITIES OF FRACTIONS OF ETHYL ACETATE FRACTION OF THE WATER EXTRACT OF *ARTOCARPUS HETEROPHYLLUS* SENESCENT LEAVES

K. S. S. P. Fernando ¹, U. G. Chandrika ², A. K. E. Goonathilake ³, M. I. Choudhary ⁴, Chayanika Padumadasa ^{*1} and A. M. Abeysekera ¹

Department of Chemistry ¹, Faculty of Applied Sciences, Department of Biochemistry ², Department of Pharmacology ³, Faculty of Medical Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka.

International Centre for Chemical and Biological Sciences ⁴, University of Karachi, Pakistan.

Keywords:

Artocarpus heterophyllus,
Hypoglycaemic, Anti-Diabetic,
Antioxidant, A- Glucosidase inhibitory,
Antiglycation, Anti-inflammatory

Correspondence to Author:

Dr. Chayanika Padumadasa

Senior Lecturer,
Department of Chemistry,
University of Sri Jayewardenepura,
Gangodawila, Nugegoda, Sri Lanka.

E-mail: chayanika@sjp.ac.lk

ABSTRACT: *Artocarpus heterophyllus* belongs to the family Moraceae. In Sri Lankan traditional medicine the water extract of *A. heterophyllus* senescent leaves is used to control diabetes mellitus. The hypoglycemic activity of ethyl acetate fraction of water extract of senescent leaves has been reported. Ethyl acetate fraction (EA/W) was fractionated using sephadex LH-20 column chromatography using the solvent systems: dichloromethane/hexane (4:1), dichloromethane/acetone (3:2), dichloromethane/acetone (1:4), dichloromethane/methanol (1:1) and methanol to produce five fractions. EA/W and fractions 1-5 were subjected to *in-vitro* antioxidant, α - glucosidase inhibitory, antiglycation and anti-inflammatory activity studies. Fraction 4 exhibited the highest DPPH radical scavenging activity ($IC_{50} = 21.69 \pm 0.31 \mu\text{g/mL}$) and α - glucosidase inhibitory activity ($IC_{50} = 0.4 \pm 0.01 \mu\text{g/mL}$) which were greater than the standards gallic acid and acarbose respectively and EA/W. Fractions 3 and 4 showed higher antiglycation activity ($IC_{50} = 0.44 \pm 0.04 \text{ mg/mL}$ and $0.30 \pm 0.01 \mu\text{g/mL}$ respectively) and higher anti-inflammatory activity ($IC_{50} = 24.4 \pm 3.8$ and $16.9 \pm 0.1 \mu\text{g/mL}$ respectively) than any other fraction or EA/W. However, these were less than the standards rutin and ibuprofen respectively. The results will be of potential use for the development of a safe and effective anti-diabetic drug from senescent leaves of *A. heterophyllus*.

INTRODUCTION: *Artocarpus heterophyllus*, which belongs to the family Moraceae is a common tree in Sri Lanka. It is known as 'Kos' in Sinhalese. There are many ethno medical usages reported for various parts of the plant ^{1, 2, 3, 4, 5}. The water extract of senescent leaves of *A. heterophyllus* used to control diabetes mellitus in Sri Lankan traditional medicine ^{6, 7}.

It has been shown that the aqueous extract of *A. heterophyllus* senescent leaves significantly lowered the fasting blood sugar levels and markedly improved glucose tolerance in animal models and in human subjects ⁸⁻¹⁰.

A recent study showed the hypoglycemic activity of the ethyl acetate fraction of the aqueous extract of *A. heterophyllus* senescent leaves was greater than that of tolbutamide, a sulphonyl urea drug commonly used for treatment of hyperglycemia ¹¹. Further, it has been reported that active compounds are soluble in ethyl acetate ^{12, 13}. Diabetes mellitus is a syndrome of chronic hyperglycemia due to relative insulin deficiency, resistance or both ¹⁴. The prevalence of the disease has increased all over

<p>QUICK RESPONSE CODE</p>	<p>DOI: 10.13040/IJPSR.0975-8232.9(6).2424-30</p> <p>Article can be accessed online on: www.ijpsr.com</p>
<p>DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.9(6).2424-30</p>	

the world during the last twenty years and is of huge concern, not only in Sri Lanka but also worldwide^{15, 16}. Long-term complications of diabetes mellitus include retinopathy, nephropathy, neuropathy, rheumatoid arthritis, osteoporosis and alzheimer's disease^{14, 17, 18, 19}. Further, diabetic patients have an increased rate of atherosclerotic, cardiovascular, peripheral arterial and cerebrovascular disease, hypertension and abnormalities of lipoprotein metabolism leading to mortality and morbidity¹⁸.

Two types of medication are used in the western world for the management of diabetes mellitus. One is to maintain blood glucose levels while the other is to minimize its associated complications. However, controlling blood sugar levels still remains a challenge. We have already reported *in-vivo* hypoglycemic and anti-diabetic activities of fractions of the ethyl acetate fractions of the aqueous extract of *A. heterophyllum* senescent leaves²⁰.

Here, we report *in-vitro* antioxidant, antiglycation, α -glucosidase inhibitory and anti-inflammatory activities of fractions of the ethyl acetate fraction of the aqueous extract of *A. heterophyllum* senescent leaves. It is of paramount importance that any remedy used in diabetes mellitus should have the capability to maintain blood glucose levels and minimize its associated complications. With that respect, the results will be of potential use for the development of a safe and effective anti-diabetic drug from senescent leaves of *A. heterophyllum*.

MATERIALS AND METHODS: DPPH (1,1-diphenyl-2-picrylhydrazyl) was purchased from Wako Chemicals Inc. (USA). α -Glucosidase enzyme was purchased from My Biosource Inc. (USA). Bovine serum albumin, methylglyoxal (MGO), *p*-nitrophenyl- α -D-glucopyranoside (pNPG), Hanks' balanced salt solution containing calcium chloride and magnesium chloride (HBSS), gallic acid ($\geq 98\%$) were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA).

Serum Oponized Zymosan (SOZ) was purchased from Fluka Chemie (Buchs, Switzerland). 3-Aminophthalhydrazide (Luminol) was obtained from Research Organics Inc. (Cleveland, OH, USA). Other chemicals and reagents were of analytical grade and purchased from Sigma-Aldrich

Co. (St. Louis, MO, USA). Water when used was distilled using GFL distillation apparatus. Microplate reader (SpectraMax 340PC384) and Luminometer (Labsystems, Helsinki, Finland) were used for respective assays.

Plant Material: Senescent leaves of *A. heterophyllum* were collected from a plant (Cultivar *Waraka*) growing in a home garden in Wijerama in the Colombo district with permission from the home owner. The material was authenticated by Mr. Isuru Kariyawasam of the Department of Botany, University of Sri Jayewardenepura and a voucher specimen (B7/006(SJP)) has been deposited in the herbarium, Department of Botany, University of Sri Jayewardenepura. The leaves were washed, air-dried for 3 hours, crushed using a mechanical blender and used for extractions.

Ethyl Acetate Fraction of the Water Extract of *A. heterophyllum* Leaves (EA/W): Crushed senescent leaves of *A. heterophyllum* (500 g) was extracted using distilled water (2500 mL) upon refluxing as previously reported²⁰. The resulting extract was allowed to cool to room temperature. Excess ethanol was added to precipitate the high molecular weight fraction and extracted with ethyl acetate (300 mL \times 6) also as previously reported²⁰. Combined ethyl acetate extracts were evaporated under reduced pressure to obtain a brownish-black sticky solid (1.2 g) (EA/W). This was repeatedly done to obtain 14 g of EA/W.

Fractionation of EA/W: EA/W (1.2 g) was fractionated using sephadex LH-20 column chromatography as previously reported²⁰. Column was eluted with 5 different solvent systems and fractions were collected separately. Fraction 1 was eluted with dichloromethane/hexane 4:1 (1 L) and fraction 2, 3, 4 and 5 were eluted with dichloromethane/acetone 3:2 (1 L), dichloromethane/acetone 1:4 (0.9 L), dichloromethane/ methanol 1:1 (1 L) and methanol (1 L) respectively.

The weights of each fraction after evaporation of the solvents were obtained and distribution of compounds were analyzed by TLC using ethyl acetate: dichloro-methane: methanol: formic acid (58:38:2:2) and ethyl acetate: formic acid: glacial acetic acid: water (100:11:11:27) as solvent systems.

In-vitro Studies: EA/W and fractions 1-5 were subjected for *in-vitro* antioxidant, antiglycation, α -glucosidase inhibitory and anti-inflammatory activity studies:

In each assay, initially the % inhibition of EA/W and fractions 1-5 were calculated using the following formula.

$$\% \text{ Inhibition} = [(A_0 - A_1) / A_0] \times 100$$

A_1 = Absorbance/emission of sample

A_0 = Absorbance/emission of control

EA/W and fractions 1-5 were subjected for determination of IC_{50} values in the respective assay only if % inhibition was 50% or more at a concentration 0.5 mg/mL.

2, 2-Diphenyl-1-picrylhydrazyl (DPPH) Radical Scavenging Assay: The antioxidant activity was determined using the DPPH radical scavenging assay according to a previously published method²¹. A concentration series of EA/W (500 μ g/mL to 15.625 μ g/mL) was prepared in DMSO. DPPH solution of 0.3 mM was prepared using absolute ethanol. From each solution of EA/W, 5 μ L aliquot was pipetted into a well in a 96-well microplate. Then 95 μ L of DPPH solution was added and incubated for 30 min in the dark at 37 °C. The absorbance was measured at 517 nm. Gallic acid was used as the positive control. Negative control contained DMSO while blank contained ethanol. The IC_{50} values were calculated using the EZ-Fit Enzyme kinetics software program (Perrella Scientific Inc., Amherst, MA, USA) and compared to that of the positive control. Experiments were performed in triplicate. The same procedure was carried out for fractions 2, 3 and 4.

α -Glucosidase inhibition Assay: α -Glucosidase inhibitory activity was determined using α -glucosidase inhibition assay according to a previously published method²². A concentration series of EA/W (7.8 μ g/mL to 0.13125 μ g/mL) was prepared in DMSO. Phosphate saline buffer of 50 mM was prepared. From each solution of EA/W 20 μ L, buffer 135 μ L and enzyme 20 μ L were pipetted into a well in a 96-well microplate and incubated for 15 min at 37 °C. After incubation the absorbance was measured at 400 nm. Then 25 μ L of the substrate pNPG was added and after 30 minutes the

absorbance was measured at 400 nm. Acarbose was used as the positive control.

Negative control contained DMSO. The IC_{50} values were calculated using the EZ-Fit Enzyme kinetics software program (Perrella Scientific Inc., Amherst, MA, USA) and compared to that of the positive control. Experiments were performed in triplicate. The same procedure was carried out for fractions 3, 4 and 5.

Antiglycation Assay: Antiglycation activity was determined using the antiglycation assay according to a previously published method²³. A concentration series of fraction 3 (0.5 mg/mL to 0.125 mg/mL) was prepared using 0.1 M phosphate buffer (pH 7.4). Bovine Serum Albumin (BSA) (10 mg/mL) solution was prepared using 0.1M phosphate buffer. Test sample (20 μ L), BSA (50.0 μ L), 14 mM MGO (50.0 μ L) and phosphate buffer (80 μ L) were pipetted into a well in a 96-well microplate and incubated under sterile conditions at 37 °C for 9 days. After which the fluorescence was measured at the excitation and emission wavelengths at 330 nm and 420 nm respectively.

Rutin was used as the positive control. Phosphate buffer (0.1 M) was used as the negative control. The IC_{50} values were calculated using the EZ-Fit Enzyme kinetics software program (Perrella Scientific Inc., Amherst, MA, USA) and compared to that of the positive control. Experiments were performed in triplicate. The same procedure was carried out for fractions 4. The experiment was carried out in triplicate.

Anti-inflammatory Assay: Anti-inflammatory activity was determined by oxidative burst assay using luminol-enhanced chemiluminescence assay according to a previously published method²⁴.

A 25 μ L cell suspension of human whole blood (obtained from healthy volunteers working at the University of Karachi with consent) (diluted 1:200) in Hanks Balanced Salt Solution, containing calcium chloride and magnesium chloride (HBSS) was incubated with 25 μ L of EA/W in HBSS at three different concentrations (10, 50 and 250 μ g/mL) each in a separate well in a 96-well plate at 37 °C for 15 min. Medium HBSS with cell suspension was employed as the negative control.

Test was carried out in white half area of 96-well plate. Incubation was performed in the thermostat chamber of Luminometer. The ROS production was initiated by the addition of 25 μL of SOZ in HBSS (20 mg/mL) into each well except for the blank solution. Thereafter, 25 μL of intracellular reactive oxygen species detecting probe, luminol ($7 \times 10^5 \text{ M}$) was added into each reaction mixture except blank wells (containing only HBSS).

Chemiluminescence peaks were recorded using a Luminometer in terms of relative light units (RLU). Ibuprofen was used as the positive control. The percentage of inhibition was calculated in comparison to the negative control in the maximum luminescence (the height of the peak). IC_{50} value was calculated using the EZ-Fit Enzyme kinetics software program (Perrella Scientific Inc. Amherst, MA, USA). The same procedure was carried out for fractions 1 - 4.

Statistical Analysis: The results are represented as the $\text{IC}_{50} \pm \text{SEM}$. Every statistical analysis was performed with one-way ANOVA, followed by student *T* test using Minitab 17.0 software. Differences were accepted as statistically significant at $P \leq 0.05$.

RESULTS AND DISCUSSION: EA/W and fractions 1-5 obtained from Sephadex LH- 20 column were tested for their *in-vitro* antioxidant activity through DPPH radical scavenging activity, anti-diabetic activity through α -glucosidase inhibition and antiglycation assays and anti-inflammatory activity through oxidative burst assay. EA/W and fractions 1-5 were subjected for determination of IC_{50} values only if % inhibition was 50% or more at concentration 0.5 mg/mL in the respective assay. The results of *in-vitro* DPPH radical scavenging, α -glucosidase inhibition, antiglycation and oxidative burst assays are given in **Table 1**.

TABLE 1: IC_{50} VALUES OF EA/W AND FRACTIONS IN DPPH RADICAL SCAVENGING, α -GLUCOSIDASE INHIBITION, ANTIGLYCATION AND OXIDATIVE BURST ASSAYS

Sample/ standard	Assay			
	DPPH radical scavenging ($\mu\text{g/mL}$)	α -Glucosidase inhibition ($\mu\text{g/mL}$)	Antiglycation (mg/mL)	Oxidative burst ($\mu\text{g/mL}$)
EA/W	29.26 ± 0.71	1.90 ± 0.57	nd	27.4 ± 2.0
Fraction 1	nd	nd	nd	71.3 ± 7.6
Fraction 2	108.34 ± 0.45	Not determined*	nd	70.7 ± 10.2
Fraction 3	29.31 ± 0.45	51.00 ± 0.98	0.44 ± 0.04	24.4 ± 3.8
Fraction 4	21.69 ± 0.31	0.40 ± 0.01	0.30 ± 0.01	16.9 ± 0.1
Fraction 5	nd	8.60 ± 0.57	nd	nd
Gallic acid	23.46 ± 0.43			
Acarbose		0.54 ± 0.01		
Rutin			0.18 ± 0.01	
Ibuprofen				11.8 ± 1.91

All values are presented as $\text{IC}_{50} \pm \text{SEM}$, $n = 3$. nd = not determined as % inhibition is less than 50% at concentration 0.5 mg/mL in the respective assay.

Antioxidant Activity: Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced due to normal cellular metabolism. These are playing dual role in the body, hence they can be harmful or beneficial to living systems. Beneficial effects occur at low or moderate concentrations of ROS or RNS. Over production of ROS or RNS or deficiency in antioxidants leads to a state of imbalance between ROS/RNS and antioxidants and causes a state called oxidative stress. At this stage high concentration of ROS/ RNS causes oxidative damage to DNA, lipids, and proteins which results in degradative effects that contributes to human diseases such as diabetes mellitus, cancer,

cardiovascular diseases, atherosclerosis, arthritis, and neurodegenerative diseases²⁵.

Increasing evidences have suggested that while oxidative stress plays a major role in the pathogenesis of diabetes mellitus it also appears to be the pathogenic factor in underlying diabetic complications^{26, 27, 28, 29, 30, 31, 32}. Free radical scavengers or antioxidants provide protection of cells against oxidative damage²⁵. The results of DPPH radical scavenging assay are given in **Table 1**. Fraction 4 exhibited highest DPPH radical scavenging activity ($\text{IC}_{50} = 21.69 \pm 0.31 \mu\text{g/mL}$) which was greater than that of EA/W ($\text{IC}_{50} = 29.26$

$\pm 0.71 \mu\text{g/mL}$). DPPH radical scavenging activity of fraction 4 was also greater than that of gallic acid ($\text{IC}_{50} = 23.46 \pm 0.43$). DPPH radical scavenging activity of fraction 3 ($\text{IC}_{50} = 29.31 \pm 0.45 \mu\text{g/mL}$) was similar to that of EA/W. Gallic acid is a commonly used standard for antioxidant assays²¹. According to these results, fraction 4 possesses better antioxidant activity than gallic acid.

α -Glucosidase Inhibition Assay: α -Glucosidase is a membrane bound enzyme located in the epithelium of the small intestine that breaks down carbohydrates to glucose by catalyzing the cleavage of $\alpha(1 \rightarrow 4)$ bonds present in carbohydrates²². Compounds capable of inhibiting the intestinal α -glucosidase enzyme can slow the digestion of carbohydrates thereby reducing the uptake of carbohydrate by the small intestine³³.

The results of α -glucosidase inhibitory assay are given in **Table 1**. According to the results obtained, fraction 4 showed the highest α -glucosidase inhibitory activity ($\text{IC}_{50} = 0.40 \pm 0.01 \mu\text{g/mL}$), which was greater than that of EA/W ($\text{IC}_{50} = 1.90 \pm 0.57$). The α -glucosidase inhibitory activity of fraction 4 was also greater than that of the acarbose ($\text{IC}_{50} = 0.54 \mu\text{g/mL}$). Acarbose is a commonly used standard for α -glucosidase inhibition assays²². According to these results, fraction 4 possesses better α -glucosidase inhibitory activity than acarbose.

Antiglycation Assay: Glucose reacts with amino groups on plasma proteins during long standing hyperglycaemic state in diabetes mellitus. This occurs under normal physiological conditions in the human body through a non-enzymatic process known as glycation^{23, 34}. Protein glycation and formation of advanced glycation end products (AGEs) play a significant role in the pathogenesis of diabetic complications that include retinopathy, neuropathy, nephropathy and cardiovascular disease³⁴. In addition, AGEs also lead to other diseases such as rheumatoid arthritis, alzheimer's disease, osteoporosis and even aging^{35, 36}.

The results of antiglycation assay are given in **Table 1**. According to the results obtained fractions 3 and 4 showed similar antiglycation activities with IC_{50} values 0.44 ± 0.04 and $0.30 \pm 0.01 \text{ mg/mL}$ respectively. However, the antiglycation activity of these fractions was less than that of rutin, which

exhibited an IC_{50} value of $0.18 \pm 0.01 \text{ mg/mL}$. Rutin is a commonly used standard in antiglycation assays. According to these results, fractions 3 and 4 possess antiglycation activity but not as much as the standard used.

Anti-inflammatory Activity: Diabetes mellitus is associated with elevated levels of inflammation. Further, poorly controlled diabetes mellitus involves increased susceptibility to infections^{14, 37}. Oxidative burst is an important step in bacterial killing. It involves a series of metabolic events that take place when phagocytes are stimulated, resulting in the production of superoxide, hydrogen peroxide, and other more potent oxidizing radicals. This can be quantified by chemiluminescence assay. Chemiluminescence is based on the amplification of natural luminescence emitted when ROS are released during phagocytosis.

The results of oxidative burst assay using chemiluminescence are given in **Table 1**. Fractions 3 ($\text{IC}_{50} = 24.4 \pm 3.8 \mu\text{g/mL}$) and 4 ($\text{IC}_{50} = 16.9 \pm 0.1 \mu\text{g/mL}$) exhibited better anti-inflammatory activity than EA/W ($\text{IC}_{50} = 27.4 \pm 2.0 \mu\text{g/mL}$) and lesser activity than ibuprofen ($\text{IC} = 11.8 \pm 1.91 \mu\text{g/mL}$), a widely used drug for inflammatory diseases. According to these results, fractions 3 and 4 possess anti-inflammatory activity but not as much as the standard used.

CONCLUSION: EA/W and fractions 1-5 of the ethyl acetate fraction of the aqueous extract of *A. heterophyllum* senescent leaves were subjected for *in-vitro* antioxidant, α -glucosidase inhibitory, antiglycation and anti-inflammatory activity studies. Of all the fractions tested, fraction 4 gave best results in antioxidant and α -glucosidase inhibitory activity studies while fractions 3 and 4 gave best results in antiglycation and anti-inflammatory activity studies. Further, we have already reported *in-vivo* hypoglycaemic and anti-diabetic activities of fractions 3 and 4²⁰.

It is of paramount importance that any remedy used in diabetes mellitus should have the capability to maintain blood glucose levels and minimize its associated complications. With that respect, these results will be of potential use for the development of a safe and effective anti-diabetic drug from senescent leaves of *A. heterophyllum*.

ACKNOWLEDGEMENT: The authors are thankful to the International Centre for Chemical and Biological Sciences, University of Karachi, Pakistan for providing assistance for the research project.

CONFLICT OF INTEREST: The authors declare that they have no conflict of interest.

REFERENCES:

- Kalaiselvan M and Gopalan R: Ethnobotanical studies on selected wild medicinal plants used by irula tribes of bolampatty valley, Nilgiri Biosphere Reserve (NBR), Southern Western Ghats, India. *Asian Journal of Pharmaceutical and Clinical Research* 2014; 1: 23-6.
- Kavishankar GB, Lakshmidhevi N, Murthy SM, Prakash HS and Niranjana SR: Diabetes and medicinal plants-A review. *International Journal of Pharmaceutical and Biomedical Sciences* 2011; 2: 65-80.
- Rajendran N and Ramakrishnan J: Polyphenol analysis and antitumor activity of crude extracts from tegmen of *Artocarpus heterophyllus*. *The Internet Journal of Alternative Medicine*. 2008; 7(2): 61-3.
- Khan MR, Omoloso AD and Kihara M: Antibacterial activity of *Artocarpus heterophyllus*. *Fitoterapia* 2003; 74: 501-5.
- Patel RM and Patel SK: Cytotoxic activity of methanolic extract of *Artocarpus heterophyllus* against A549, HeLa and MCF-7 cell lines. *Journal of Applied Pharmaceutical Science* 2011; 1(7): 167-171.
- Attygalle J: Sinhalese MateriaMedica. M.D. Gunasena and Co. Ltd. Colombo, 2nd Edition 1952.
- Anonymous. Thalpathe Piliyam. Department of Ayurveda, Colombo.1993.
- Fernando MR and Thabrew MI: Extra-pancreatic effects contributing to the hypoglycaemic activity of *Artocarpus heterophyllus*. *The Ceylon Journal of Medical Science* 2001; 44: 1-10.
- Fernando MR, Thabrew MI and Karunanayake EH: Hypoglycaemic activity of some medicinal plants in Sri Lanka. *GeneralPharmacology*1990; 21: 779-82.
- Fernando MR, Wickramasinghe SMDN, Thabrew MI, Ariyananda PL and Karunanayake EH: Effect of *Artocarpus heterophyllus* and *Asteracanthus longifolia* on glucose tolerance in normal human and maturity onset diabetic patients. *Journal of Ethnopharmacology* 1991; 81: 277-82.
- Chandrika UG, Wedage WS, Wickramasinghe SMDN and Fernando WS: Hypoglycaemic action of the flavonoid fraction of *Artocarpus heterophyllus* leaf. *African Journal of Traditional Complementary and Alternative medicines* 2006; 3(2): 42-50.
- Chackrewarthy S, Thabrew MI, Weerasuriya M and Jayasekera S: Evaluation of the hypoglycemic and hypolipidemic effects of an ethyl acetate fraction of *Artocarpus heterophyllus* (jak) leaves in streptozotocin-induced diabetic rats. *Pharmacognosy Magazine* 2010; 6(23): 186-90.
- Chackrewarthy S and Thabrew MI: Glucose tolerance. INTECH 2012.<http://creativecommons.org/licenses/by/3.0>.
- Kumar P and Clark M: Kumar & Clark's Clinical Medicine. Saunders, Elsevier, Spain, Edition 7, 2009.
- International Diabetes Federation. Diabetes Atlas, Brussels, Edition 6, 2013.
- <http://www.idf.org/diabetesatlas>.
- King H, Aubert RE and Herman WH: Global Burden of Diabetes 1995 - 2025 Prevalence, numerical estimates and projections. *Diabetes Care* 1998; 21(9): 1414-31.
- American Diabetes Association: Standards of Medical Care in Diabetes 2014. *Diabetes Care* 2014; 37(1): S14-S78.
- American Diabetes Association: Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2012; 35(1): S64 - S71.
- Deshpande AD, Harris-Hayes M and Schootman M: Epidemiology of diabetes and diabetes-related complications. *Physical Therapy*2008; 88: 1254-64.
- Fernando KSSP, Abeyssekera AM, Padumadasa C, Goonathilake AKE, Choudhary MI, Rahman MH, Thadani VM and ChandrikaUG: Hypoglycaemic activity of fractions of ethyl acetate fraction of the water extract of *Artocarpus heterophyllus* senescent leaves. *International Journal of Ayurveda and Pharma Research* 2017; 5(2): 1-6.
- Thadhani VM, Choudhary MI, Ali S, Omar I, Siddique H and Karunaratne V: Antioxidant activity of some lichen metabolites. *Natural Products Research*2011; 25(19): 1827-37.
- Bischoff HBAG: Pharmacology of α -glucosidase inhibition. *European Journal of Clinical Investigation* 1994; 24(3): 3-10.
- Rahbar S and Figarola JL: Novel inhibitors of advanced glycation end products. *Archives of Biochemistry and Biophysics* 2003; 419: 63-79.
- Helfand S, Werkmeister J and Roder J: Chemiluminescence response of human natural killer cells. I. The relationship between target cell binding, chemiluminescence, and cytolysis. *The Journal of Experimental Medicine* 1982; 156: 492-505.
- Halliwell B: Antioxidants and human disease: A General Introduction. *Nutrition Reviews*1997; 55: S44-S52.
- Maritim AC, Sanders RA and Watkins JB: Diabetes, oxidative stress, and antioxidants: A review. *Journal of Biochemical and Molecular Toxicology* 2003; 17(1): 24-37.
- Maiese K: New Insights for Oxidative stress and diabetes mellitus. *Oxidative Medicine and Cellular Longevity* 2015; 1-17.
- Moussa SA:Oxidative Stress In Diabetes Mellitus. *Romanian Journal of Biophysics*2008; 18(3): 225-36.
- Chikezie PC, Ojiako OA and Ogbuji AC: Oxidative stress in diabetes mellitus. *Integrative Obesity and Diabetes* 2015; 1(3): 71-9.
- Lipinski B: Pathophysiology of oxidative stress in diabetes mellitus. *Journal of Diabetes Complications* 2001; 15: 203-10.
- Wolf SP, Jiang ZY and Hunt JV: Protein glycation and oxidative stress in diabetes mellitus and ageing. *Free Radic. Biol. Med.* 1991; 10: 339-52.
- Wolf SP: Diabetes mellitus and free radicals.Br. Med. Bull.1993; 49(3): 642 -52.
- Lorenzati B, Zucco C, Miglietta S, Lamberti F and Bruno G: Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. *Pharmaceuticals* 2010; 3: 3005-20.
- Karmakar PS and Goswami RP: Advanced Glycation End Products (AGEs): It's Role in the Pathogenesis of Diabetic Complications. *Medicine updates*2012; 22: 277-82.
- Cantero A-V, Portero-Oti NM, Ayala VR, Auge N, Sanson M, Elbaz M, Thiers J-C, Pamplona R, Salvayre R and Ne`Gre-Salvayre A: Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction

- of PDGF receptor-: implications for diabetic atherosclerosis. FASEB Journal 2007; 21: 3096-106.
36. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S and Takeuchi M: Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. American Journal of Alzheimer's disease and Other Dementias 2006; 21: 197-208.
37. Graves DT, Liu R and Oates TW: Diabetes-enhanced inflammation and apoptosis-impact on periodontal pathosis. Periodontology 2000; 45: 128-37.

How to cite this article:

Fernando KSSP, Chandrika UG, Goonathilake AKE, Choudhary MI, Padumadasa C and Abeysekera AM: *In-vitro* biological activities of fractions of ethyl acetate fraction of the water extract of *Artocarpus heterophyllus* senescent leaves. Int J Pharm Sci Res 2018; 9(6): 2424-30. doi: 10.13040/IJPSR.0975-8232.9(6).2424-30.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)